Peregrine Pharmaceuticals  

(Public, NASDAQ:PPHM)   Watch this stock  
Find more results for PPHM
1.83
-0.01 (-0.54%)
Apr 24 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.75 - 1.88
52 week 1.11 - 3.18
Open 1.86
Vol / Avg. 1.43M/2.98M
Mkt cap 322.96M
P/E     -
Div/yield     -
EPS -0.22
Shares 176.48M
Beta 1.39
Inst. own 15%
Jul 7, 2014
Q4 2014 Peregrine Pharmaceuticals Earnings Release (Estimated) Add to calendar
Apr 8, 2014
Peregrine Pharmaceuticals at Biotechnology Industry Organization Asia International Conference
Mar 10, 2014
Peregrine Pharmaceuticals at ROTH Conference
Mar 7, 2014
Q3 2014 Peregrine Pharmaceuticals Earnings Conference Call
Mar 7, 2014
Q3 2014 Peregrine Pharmaceuticals Earnings Release
Mar 4, 2014
Peregrine Pharmaceuticals at Cowen Health Care Conference
Feb 25, 2014
Peregrine Pharmaceuticals at RBC Capital Markets Healthcare Conference
More events from DailyFinance »    

Key stats and ratios

Q1 (Jan '14) 2013
Net profit margin -250.30% -137.34%
Operating margin -250.79% -138.58%
EBITD margin - -125.74%
Return on average assets -59.28% -81.23%
Return on average equity -85.99% -179.17%
Employees 182 -
CDP Score - -

Address

14282 Franklin Avenue
TUSTIN, CA 92780
United States - Map
+1-714-5086000 (Phone)
+1-714-8385817 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Peregrine Pharmaceuticals, Inc. is a biopharmaceutical company with a portfolio of monoclonal antibodies in clinical trials for the treatment and diagnosis of cancer. The Company has two platforms and are pursuing multiple clinical programs in cancer with its lead immunotherapy candidate bavituximab, its PS-targeting agent, 124I-PGN650 (PGN650), and its brain cancer therapy Cotara. Bavituximab is the Company�s therapeutic PS-targeting antibody. PGN650 is its PS-targeting imaging agent. The Company has conducted three randomized Phase II trials for bavituximab in combination with standard chemotherapy in both front and second-line NSCLC as well as front-line pancreatic cancer. In addition, it has four ongoing ISTs evaluating bavituximab with additional drug combinations in additional oncology indications.

Officers and directors

Carlton M. Johnson Jr. Independent Chairman of the Board
Age: 53
Bio & Compensation  - Reuters
Steven W. King President, Chief Executive Officer, Director
Age: 49
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Paul J. Lytle Chief Financial Officer
Age: 45
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Mark R. Ziebell Vice President, General Counsel, Corporate Secretary
Age: 49
Bio & Compensation  - Reuters
Shelley P.M. Fussey Ph.D. Vice President - Intellectual Property
Age: 47
Bio & Compensation  - Reuters
Joseph S. Shan Vice President - Clinical & Regulatory Affairs
Age: 40
Bio & Compensation  - Reuters
Stephen T. Worsley MBA Vice President - Business Development
Bio & Compensation  - Reuters
David H. Pohl Independent Director
Age: 76
Bio & Compensation  - Reuters
Eric S. Swartz Independent Director
Age: 56
Bio & Compensation  - Reuters